Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50:S11–S16. https://doi.org/10.1016/j.semarthrit.2020.04.008

Article  PubMed  Google Scholar 

Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H et al (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1859–1922. https://doi.org/10.1016/S0140-6736(18)32335-3

Article  Google Scholar 

Schlesinger N (2007) Diagnosis of gout. Minerva Med 98:759–767

CAS  PubMed  Google Scholar 

Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907–1912. https://doi.org/10.1136/ard.2010.128454

Article  CAS  PubMed  Google Scholar 

TherapeuticGuidelines (2021) Gout. https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Rheumatology&topicfile=gout&guidelinename=Rheumatology&sectionId=toc_d1e232#toc_d1e232. Accessed 28 June 2021

Vargas-Santos AB, Neogi T (2017) Management of gout and hyperuricemia in CKD. Am J Kidney Dis 70:422–439. https://doi.org/10.1053/j.ajkd.2017.01.055

Article  CAS  PubMed  PubMed Central  Google Scholar 

Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46:623–644. https://doi.org/10.2165/00003088-200746080-00001

Article  CAS  PubMed  Google Scholar 

Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56. https://doi.org/10.1016/0002-9343(84)90743-5

Article  CAS  PubMed  Google Scholar 

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W et al (2017) The British Society for Rheumatology Guideline for the management of gout. Rheumatology (Oxford) 56:e1–e20. https://doi.org/10.1093/rheumatology/kex156

Article  CAS  PubMed  Google Scholar 

Krishnan E (2012) Reduced glomerular function and prevalence of gout: NHANES 2009–10. PLoS ONE 7:e50046. https://doi.org/10.1371/journal.pone.0050046

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohammed E, Browne LD, Kumar AUA, Adeeb F, Fraser AD, Stack AG (2019) Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: a national study. PLoS ONE 14:e0210487. https://doi.org/10.1371/journal.pone.0210487

Article  CAS  PubMed  PubMed Central  Google Scholar 

KDIGO (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf. Accessed 25 Mar 2024

Day RO, Kannangara DR, Hayes JM, Furlong T (2012) Successful use of allopurinol in a patient on dialysis. BMJ Case Rep 2012:bcr0220125814. https://doi.org/10.1136/bcr.02.2012.5814

UpToDate (2023) Allopurinol: drug information. https://www.uptodate.com/contents/allopurinol-drug-information?source=mostViewed_widget. Accessed 28 Nov 2023.

Murea M, Tucker BM (2019) The physiology of uric acid and the impact of end-stage kidney disease and dialysis. Semin Dial 32:47–57. https://doi.org/10.1111/sdi.12735

Article  PubMed  Google Scholar 

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D et al (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467–473. https://doi.org/10.7326/M18-0850

Article  PubMed  Google Scholar 

Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, McInerney P et al (2021) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. https://doi.org/10.11124/JBIES-20-00167

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13

Article  PubMed  PubMed Central  Google Scholar 

Rohatgi A (2022) WebPlotDigitizer. https://automeris.io/WebPlotDigitizer. Accessed 2 Mar 2022

Atkinson AJ (2016) Pitfalls in the calculation of hemodialysis clearance and in the assessment of dialysis efficacy. Transl Clin Pharmacol 24:153–156

Google Scholar 

Fick A (1870) Ueber die Messung des Blutquantums in den Herzventrikeln

Yeo E, Palmer SC, Chapman PT, Frampton C, Stamp LK (2019) Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. Intern Med J 49(7):838–842. https://doi.org/10.1111/imj.14163

Article  CAS  PubMed  Google Scholar 

Wilson LC, Ward J, Wright DFB, Green SC, Stocker SL, Putt TL, Schollum JBW et al (2024) The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout. Nephrology (Carlton) 29:547–550. https://doi.org/10.1111/nep.14306

Article  CAS  PubMed  Google Scholar 

Arenas MD, Soriano R, Andres M, Pascual E (2021) Serum urate levels of hemodialyzed renal patients revisited. J Clin Rheumatol 27(8):E362–E366. https://doi.org/10.1097/RHU.0000000000001438

Article  PubMed  Google Scholar 

Diez-Lopez C, Perez-Contreras J, Andres M (2021) Urate levels and clearance in renal patients under peritoneal dialysis. Nucleosides Nucleotides Nucleic Acids 40(7):720–731. https://doi.org/10.1080/15257770.2021.1934482

Article  CAS  PubMed  Google Scholar 

Rohn B, Jansing W, Seibert FS, Pfab T, Cinkilic O, Pasfall J, Schmidt S et al (2020) Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients. Ren Fail 42:1067–1075. https://doi.org/10.1080/0886022X.2020.1835674

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elion GB, Benezra FM, Beardmore TD, Kelley WN (1980) Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol 122A:263–267. https://doi.org/10.1007/978-1-4615-9140-5_43

Article  CAS  PubMed  Google Scholar 

Shelmadine B, Bowden RG, Wilson RL, Beavers D, Hartman J (2009) The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. Anadolu Kardiyol Derg 9(5):385–389

PubMed  Google Scholar 

Reiter S, Engelleiter R, Proske H, Muller A, Van Der Woude FJ, Duley JA, Simmonds HA (1998) Severe debilitating polyarticular gout and terminal renal failure in an allopurinol “non-responder.” Adv Exp Med Biol 431:51–55. https://doi.org/10.1007/978-1-4615-5381-6_10

Article  CAS  PubMed  Google Scholar 

KDOQI (2015) KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66:884–930. https://doi.org/10.1053/j.ajkd.2015.07.015

Article  Google Scholar 

KDOQI (2006) Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 48(Suppl 1):S98-129. https://doi.org/10.1053/j.ajkd.2006.04.006

Article  Google Scholar 

Rutherford E, Ireland S, Mangion K, Stewart GA, MacGregor MS, Roditi G, Woodward R et al (2021) A randomized, controlled trial of the effect of allopurinol on left ventricular mass index in hemodialysis patients. Kidney Int Rep 6:146–155. https://doi.org/10.1016/j.ekir.2020.10.025

Article  PubMed  Google Scholar 

Wright D, Doogue M, Barclay M, Chapman P, Cross N, Irvine J, Stamp L (2017) A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur J Clin Pharmacol 73:71–78. https://doi.org/10.1007/s00228-016-2133-y

Article  CAS  PubMed  Google Scholar 

Hsu SC, Lee YY, Wang MC, Liu HL, Cheng MF, Huang JJ (2004) Diffuse calcinosis and intradermal tophi in a uremic patient: effect of low-calcium hemodialysis and mechanism of hypercalcemia. Blood Purif 22:224–228. https://doi.org/10.1159/000076857

Article  CAS  PubMed  Google Scholar 

Matsuda O, Otsuka M, Yamada T, Tomita K, Marumo F (1993) Therapeutic effect of hemodialysis on gouty arthritis and tophi in 2 patients with chronic renal failure. Nihon Jinzo Gakkai Shi. 35:783–789. https://doi.org/10.14842/jpnjnephrol1959.35.783

Article  CAS  PubMed